01重点学术场次Priority Sessions9 场
本专题的重点场次包含 Hot Line、LBCS、New ESC Guidelines、Ask the Trialists、Guidelines in Practice、Great Debates 等。
指南与标准3 场
New Guidelines
2026 ESC 心脏康复指南
2026 ESC Guidelines on Cardiac Rehabilitation
血脂管理2 场
LBCS
2026 预防前沿：人工智能、肥胖与个体化心血管照护
Prevention in 2026: artificial intelligence, obesity and personalised cardiovascular care
个体斑块阈值：用于选择个体化 LDL 目标以实现心血管预防个性化的因果 AI 生物世界模型
The Personal Plaque Threshold: A Causal AI Biological World Model for Selecting Individualized LDL Targets to Personalize Cardiovascular Prevention
β受体阻滞剂与缺血性卒中风险：来自随机临床试验的证据
Risk of Ischemic Stroke With Beta-Blockers: Evidence From Randomized Clinical Trials
替尔泊肽治疗肥胖成人中按体重减轻维持程度分层的心血管代谢参数：SURMOUNT MAINTAIN 试验事后分析
Cardiometabolic parameters by the degree of maintenance of weight reduction in tirzepatide-treated adults with obesity: post hoc study of SURMOUNT MAINTAIN Trial
高强度间歇训练降低老年人 10 年死亡率：Generation 100 随机对照试验
High-Intensity Interval Training Reduces 10-Year Mortality in Older Adults: The Generation 100 Randomized Controlled Trial
基于机器学习与血流动力学特征的临床决策支持系统用于基层个体化、符合指南的降压治疗（LIGHT-precision）
Machine learning and hemodynamic profile-based clinical decision support systems for personalized guideline-concordant antihypertensive treatment in primary care (LIGHT-precision)
慢性冠脉综合征伴既往心肌梗死患者停用 β 受体阻滞剂：ABYSS 与 SMART-DECISION 随机试验的汇总分析
BetaBlocker discontinuation in patients with chronic coronary syndrome, prior myocardial infarction: a pooled analysis of the ABYSS and SMART-DECISION randomised trials.
LBCS
他汀之后：下一代降脂疗法
Beyond statins: the next wave of lipid-lowering therapies
高危与极高危心血管风险患者中 inclisiran 对比贝派地酸降低 LDL-C 的头对头比较：4 期 VICTORION-CHALLENGE 试验结果
Head-to-head comparison of inclisiran vs bempedoic acid for LDL C lowering in patients with high and very high cardiovascular risk: Results from the phase 4 VICTORION-CHALLENGE trial
口服 HRS-5346（新型小分子脂蛋白(a) 抑制剂）用于脂蛋白(a) 升高且高心血管风险的成人：2 期随机双盲研究
Oral HRS-5346, a novel small molecule lipoprotein(a) inhibitor, in adults at high cardiovascular risk with elevated lipoprotein(a): a phase 2, randomized, double-blind study
急性冠脉综合征患者的方案化早期强化血脂管理（BRIDGE）：多中心前瞻性整群随机对照试验
Protocol-based early intensive lipid management in patients with acute coronary syndrome (BRIDGE): A multicenter prospective cluster-randomized controlled trial
评估 VSA003 注射液治疗中国纯合子家族性高胆固醇血症（HoFH）青少年与成人疗效和安全性的 3 期临床试验
A phase 3 clinical trial to evaluate the efficacy and safety of vsa003 injection in chinese adolescents and adults with homozygous familial hypercholesterolaemia (hofh)
依洛尤单抗对无既往心肌梗死或卒中患者致死性结局的影响：VESALIUS-CV 试验预设分析
Effects of Evolocumab on Fatal Outcomes in Patients Without a Prior Myocardial Infarction or Stroke : Pre-specified Analysis of the VESALIUS-CV Trial
长效靶向脂蛋白(a) 的 siRNA 药物 lepodisiran 对氧化磷脂的影响
Effect on Oxidized Phospholipids of Lepodisiran, an Extended Duration siRNA Targeting Lipoprotein(a)
风险预测与早筛1 场
Great Debates
焦点辩论：人工智能时代冠状动脉 CT 与心血管病预防
Great Debates: coronary computed tomography for cardiovascular disease prevention in the era of artificial intelligence
冠状动脉 CT 应用于增强心血管疾病预防
Coronary computed tomography should be used to enhance cardiovascular disease prevention
正方Charalambos AntoniadesUniversity of Oxford反方Birgitta VelthuisUniversity Medical Center Utrecht评论员Erin MichosThe Johns Hopkins University School of Medicine
冠状动脉 CT 应用于 veteran 运动员筛查
Coronary computed tomography should be used for screening veteran athletes
正方Sanjay SharmaCity St George's University of London反方Andre La GercheSt Vincent's Hospital评论员Silvia CastellettiUniversity Hospital Santa Maria della Misericordia
肥胖与代谢新药（GLP-1）1 场
Great Debates
焦点辩论：GLP-1 受体激动剂应否用于人群水平预防
Great Debate: should GLP-1 receptor agonists be used for population-level prevention?
GLP-1 受体激动剂应否用于人群水平预防
Should GLP-1 receptor agonists be used for population-level prevention?
正方John Eric DeanfieldUniversity College London反方Pasquale Perrone-FilardiUniversity of Naples Federico II评论员Marianne BennRigshospitalet
其他2 场Hot Line 1
LBCS
晚期临床试验：基因与分子疗法改写心血管疾病
Late-Breaking Clinical Trials: rewriting cardiovascular disease on gene and molecular therapies
血管生成素样蛋白 3 抗体 rivocibart 治疗纯合子家族性高胆固醇血症
Angiopoietin-like 3 antibody rivocibart for homozygous familial hypercholesterolemia
靶向 ANGPTL3 的 CRISPR-Cas9 基因编辑药物 CTX310 的效应持久性
Durability of Effects of CTX310, a CRISPR-Cas9 Gene Editing Targeting ANGPTL3
AAV8 介导的基因治疗用于纯合子家族性高胆固醇血症
AAV8-mediated gene therapy for homozygous familial hypercholesterolemia
单次给药 Kylo-11 后超长时间降低 Lp(a)：首个人体研究的最终数据
Extremely Long Duration Lp(a) Reduction Following a Single Dose of Kylo-11: Final Data from a First-in-Human Study
Hot Line
HOT LINE 2（全球首发专场）
HOT LINE 2
STAREE：他汀类药物减少老年人事件
STAREE: Statins for Reducing Events in the Elderly
AMUNDSEN：急性心肌梗死 PCI 前使用依洛尤单抗
AMUNDSEN: Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction
TRANQUILITY：帕西贝奇图（IL-6 配体单抗）每月与每季度给药靶向高危心血管风险慢性肾脏病炎症的疗效
TRANQUILITY: Efficacy of monthly and quarterly dosing of pacibekitug (IL-6 ligand mAb) targeting inflammation in CKD with high cardiovascular risk
REACT——成人一生中无症状动脉粥样硬化的患病率
REACT - Prevalence of silent atherosclerosis across adult life
ENRICH-AF：颅内出血存活房颤患者使用艾多沙班
ENRICH-AF: Edoxaban in intracranial hemorrhage survivors with atrial fibrillation
DAN-RSV：RSVpreF 疫苗预防心肺疾病住院
DAN-RSV: RSVpreF vaccine for preventing cardiorespiratory hospitalisations
02中国专家参与场次China Faculty3 场
| 中国专家参与的报告 |
|---|
| 血脂管理 · 3 项中国专家报告 |
基于机器学习与血流动力学特征的临床决策支持系统用于基层个体化、符合指南的降压治疗（LIGHT-precision） Machine learning and hemodynamic profile-based clinical decision support systems for personalized guideline-concordant antihypertensive treatment in primary care (LIGHT-precision) |
口服 HRS-5346（新型小分子脂蛋白(a) 抑制剂）用于脂蛋白(a) 升高且高心血管风险的成人：2 期随机双盲研究 Oral HRS-5346, a novel small molecule lipoprotein(a) inhibitor, in adults at high cardiovascular risk with elevated lipoprotein(a): a phase 2, randomized, double-blind study |
评估 VSA003 注射液治疗中国纯合子家族性高胆固醇血症（HoFH）青少年与成人疗效和安全性的 3 期临床试验 A phase 3 clinical trial to evaluate the efficacy and safety of vsa003 injection in chinese adolescents and adults with homozygous familial hypercholesterolaemia (hofh) |
| 其他 · 2 项中国专家报告 |
血管生成素样蛋白 3 抗体 rivocibart 治疗纯合子家族性高胆固醇血症 Angiopoietin-like 3 antibody rivocibart for homozygous familial hypercholesterolemia |
AAV8 介导的基因治疗用于纯合子家族性高胆固醇血症 AAV8-mediated gene therapy for homozygous familial hypercholesterolemia |
03本领域中国研究China Abstracts101 篇
| 研究标题 | 第一作者 | 所在机构 |
|---|---|---|
| 肥胖 · 16 篇 | ||
基于MRI的身体成分预测新发2型糖尿病 MRI-based body composition predicts incident type 2 diabetes mellitus | Shuang Zhang | 中国医学科学院北京协和医学院阜外医院 |
体重指数与急性心肌梗死患者短期结局的性别特异性关联 Sex-specific associations between body mass index and short-term outcomes in patients with acute myocardial infarction | Kang-Yin Chen | 天津医科大学第二医院 |
1999至2023年美国肥胖成人心血管死亡率趋势与差异 Trends and disparities of cardiovascular mortality among adults with obesity in the United States from 1999 to 2023 | Jing Gao | 天津市胸科医院 |
高血压合并肥胖与新发心力衰竭风险：两项前瞻性队列研究的启示 Concurrent hypertension and obesity and the risk of incident heart failure: insights from two prospective cohort studies | Rongchong Huang | 首都医科大学附属北京友谊医院 |
将久坐时间重新分配给体力活动对不同代谢肥胖表型房颤的差异化获益：前瞻性队列研究 Differential benefits of reallocating sedentary time to physical activity on atrial fibrillation across metabolic obesity phenotypes: a prospective cohort study | Boning Zhou | 中国医学科学院北京协和医学院阜外医院 |
BMI与ACS院内死亡率的关系：中国心血管协会胸痛中心注册研究的结果 The relationship between BMI and ACS in-hospital mortality: findings from the Chinese Cardiovascular Association-Chest Pain Center Registry | Tongtong Zang | 复旦大学附属中山医院 |
非ST段抬高型心肌梗死患者体重指数与全因死亡的关联 Association between body mass index and all-cause mortality in patients with non-ST-segment-elevation myocardial infarction | Jing Gao | 天津市胸科医院 |
身体圆度指数与全因死亡及心血管疾病的关联：PURE-中国研究 Associations of body roundness index with with all-cause mortality and cardiovascular diseases: the prospective urban rural epidemiology (PURE)-China study | Lingqian Hu | 中国医学科学院北京协和医学院阜外医院 |
从儿童期到成年中期BMI累积负担与亚临床心血管结局：心血管危险因素的中介作用 Cumulative burden of body mass index from childhood to mid-adulthood in relation to subclinical cardiovascular outcomes: the mediating role of cardiovascular risk factors | Tongshuai Guo | 西安交通大学第一附属医院 |
细化心血管-肾脏-代谢综合征0-3期标准：全国NHANES队列中过度肥胖的增量重分层价值 Refining the criteria of cardiovascular-kidney-metabolic syndrome stage 0-3: the incremental reclassification value of excessive adiposity in a nationwide NHANES cohort | Haixu Yu | 北京积水潭医院 |
内脏肥胖相关代谢与炎症特征独立于BMI识别晚期CKM 4期 Visceral adiposity–associated metabolomic and inflammatory signatures identify advanced CKM stage 4 independent of BMI | Chi-Hsiao Yeh | 林口长庚纪念医院 |
腹型肥胖较全身性肥胖更早、更高地增加CKM综合征风险：NHANES横断面研究 Abdominal obesity leads to earlier and higher CKM syndrome risk than general obesity: a cross-sectional NHANES study | Qian-Hui Tai | 西安交通大学第一附属医院 |
从儿童期到成年期的长期BMI负担及其变异性与中年心血管-肾脏-代谢综合征：36年队列研究 Long-term BMI burden, its variability from childhood to adulthood and cardiovascular-kidney-metabolic syndrome in midlife: a 36-year cohort study | Guilin Hu | 西安交通大学第一附属医院 |
累积中心性肥胖指数预测中年靶器官损害的比较：31年队列研究 Comparison of cumulative central obesity indices for predicting midlife target organ damage: a 31-year Cohort Study | Qian-Hui Tai | 西安交通大学第一附属医院 |
低握力与腹型肥胖对主要心血管事件的联合影响：PURE-中国队列分析 Joint effects of low grip strength and abdominal obesity on major cardiovascular events: an analysis of the prospective urban rural epidemiology (PURE)-China cohort study | Chilie Danzeng | 国家心血管病中心、阜外医院心血管疾病国家重点实验室 |
甘油三酯-葡萄糖指数及其与人体测量肥胖指标的组合对中国人群MAFLD的显著预测 Triglyceride glucose index and its combination with anthropometric obesity indicators are significant predictors of MAFLD among the Chinese population | Mingwei Wang | 杭州师范大学附属医院 |
| 生物标志物 · 14 篇 | ||
残余胆固醇与急性心肌损伤患者死亡率：回顾性队列研究 Remnant cholesterol and mortality in patients with acute myocardial injury: a retrospective cohort study | Linhao Liu | 天津医科大学总医院 |
胆固醇-高密度脂蛋白-葡萄糖指数预测心血管-肾脏-代谢综合征的发病、进展与预后：两大前瞻性队列证据 Cholesterol, high-density lipoprotein, and glucose index predict the onset, progression, and prognosis of cardiovascular-kidney-metabolic syndrome: evidence from two large prospective cohorts | Zehao Zhao | 首都医科大学附属北京安贞医院 |
FIB-4指数与心血管-肾脏-代谢综合征的分期特异性关联：人群研究 Stage specific associations between FIB-4 index and cardiovascular kidney metabolic syndrome: a population-based study | Pengxin Xie | 北京大学第三医院 |
外周血嗜酸性粒细胞计数与氯吡格雷治疗的冠心病患者血小板反应性的相关性：大样本队列研究 Correlation between peripheral blood eosinophil count and platelet reactivity in coronary heart disease patients treated with clopidogrel: a large-scale cohort study | Zihao Ke | 国家心血管病中心、阜外医院心血管疾病国家重点实验室 |
生物学年龄加速与心血管-肾脏-代谢综合征进展：PhenoAge与KDMAge的多队列比较分析 Biological age acceleration and progression of cardiovascular-kidney-metabolic syndrome: a multi-cohort comparative analysis of phenoage and KDMAge | Yitian Chen | 首都医科大学附属北京友谊医院 |
高敏C反应蛋白超越AHA PREVENT方程的心血管风险重分层改善：英国生物样本库研究 High-sensitivity C-reactive protein improves cardiovascular risk reclassification beyond the AHA PREVENT equations: a UK Biobank study | Yuzhe Yin | 国家心血管病中心、阜外医院心血管疾病国家重点实验室 |
CTI累积负担与动态轨迹与亚临床靶器官损害及心血管疾病的关系：两项纵向队列的发现 Cumulative burden and dynamic trajectories of the CTI in relation to subclinical organ damage and cardiovascular disease: findings from two longitudinal cohorts | Guilin Hu | 西安交通大学第一附属医院 |
九种血脂相关复合指数预测急性心肌梗死患者临床结局的头对头比较 Head-to-head comparison of nine lipid-related composite indices for predicting clinical outcomes in patients with acute myocardial infarction | Shao Qiang Qin | 天津医科大学第二医院 |
应激性高血糖比值与炎症-代谢-凝血特征对早发心肌梗死远期不良结局的联合关联 Joint association of stress hyperglycemia ratio and inflammatory-metabolic-coagulation profiles with long-term adverse outcomes in premature myocardial infarction | Jing Gao | 天津市胸科医院 |
基于CTI的肥胖指数对新发心血管疾病的比较表现：CHARLS的启示 Comparative performance of CTI-based adiposity indices for incident CVD: insights from CHARLS | Feiyu Zhang | 首都医科大学附属北京安贞医院 |
整合常规生物标志物的早发冠心病年轻患者2年MACCE预测模型的开发与验证：多中心研究 Development and validation of a 2-year MACCE prediction model incorporating routine biomarkers in young patients with premature coronary heart disease: a multicenter study | Jingjing Xu | 国家心血管病中心、阜外医院心血管疾病国家重点实验室 |
中国内脏脂肪指数与新发心肾代谢多病共存的关联：9年全国队列研究 Association of the Chinese visceral adiposity index with incident cardio-renal-metabolic multimorbidity: a 9-year nationwide cohort study | Ying Song | 国家心血管病中心、阜外医院心血管疾病国家重点实验室 |
MAF-5评分与cT1的心血管风险：英国生物样本库证据 MAF-5 score and cT1 for cardiovascular risk: evidence from UK Biobank | Jing Yang | 上海市徐汇区中心医院 |
系统炎症反应指数累积暴露与CKM综合征0-2期中老年人群全因死亡风险的关联 Relationship between cumulative exposure to systemic inflammation response index and risk of all-cause mortality in middle-aged and older adults with cardiovascular-kidney-metabolic syndrome stage 0–2 | Rongchong Huang | 首都医科大学附属北京友谊医院 |
| 流行病学 · 9 篇 | ||
心血管疾病、死亡与常见健康决定因素的省际差异：PURE-中国研究的启示 Provincial differences in cardiovascular disease, deaths, and common health determinants: insights from the Prospective Urban Rural Epidemiology (PURE)-China study | Xin Liu | 阜外医院 |
意义未明克隆性造血与Y染色体嵌合缺失对男性全因及心血管死亡的联合关联 Joint association of clonal hematopoiesis of indeterminate potential and mosaic loss of Y chromosome with all-cause and cardiovascular mortality in men | Ying Sun | 上海市第九人民医院 |
饮用低钙水降低血管内皮细胞活力并增加急性心肌梗死风险 Low calcium in drinking water reduces vascular endothelial cell viability and increases the risk of acute myocardial infarction | Min Liu | 河南省人民医院 |
肌酐/胱抑素C标准化比值累积暴露与变化模式和CKM 0-3期成人新发心血管疾病的关联：CHARLS分析 Associations of cumulative exposure and change patterns of the normalised creatinine-to-cystatin C ratio with incident cardiovascular disease in CKM stage 0–3 adults: a CHARLS analysis | Beibei Du | 吉林大学中日联谊医院 |
全因与心血管特异性死亡率代际分化的社会经济不平等：比较纵向分析 Diverging socioeconomic inequalities in all-cause and cardiovascular -specific mortality across generations: a comparative longitudinal analysis | Feilong Chen | 国家心血管病中心、阜外医院心血管疾病国家重点实验室 |
非酒精性脂肪肝与心血管-肾脏-代谢综合征进展的关联：英国生物样本库与中国队列证据 Association between nonalcoholic fatty liver disease and cardiovascular-kidney-metabolic syndrome progression: evidence from UK biobank and Chinese cohort | Weilan Li | 首都医科大学附属北京友谊医院 |
动态生活方式轨迹、多基因遗传风险与冠心病发病：英国生物样本库纵向研究 Dynamic lifestyle trajectories, polygenic risk, and incident coronary artery disease: a longitudinal study in the UK biobank | Qiao Ling Hou | 首都医科大学 |
青年期心血管-肾脏-代谢综合征与后续主要不良心血管事件、全因死亡及中年CKM分期的关联 Association of Cardiovascular-Kidney-Metabolic syndrome in young adulthood with subsequent major adverse cardiovascular events, all-cause mortality, and midlife Cardiovascular-Kidney -Metabolic stages | Jia-Jie Wang | 同济大学附属同济医院 |
15–39岁人群缺血性心脏病全球负担变化趋势：下降、差异与2020年后逆转 Changing trends in the global burden of ischemic heart disease among individuals aged 15–39 years: decline, disparities, and a post-2020 reversal | Xiaoyan Yang | 首都医科大学附属北京朝阳医院 |
| 代谢综合征、胰岛素与胰岛素抵抗 · 8 篇 | ||
甘油三酯-葡萄糖体重指数与非酒精性脂肪肝人群2型糖尿病的关联 Association between triglyceride-glucose body mass index and type 2 diabetes mellitus in patients with non-alcoholic fatty liver disease | Mingwei Wang | 杭州师范大学附属医院 |
04企业卫星会Industry Symposia26 个系列
赞助商分布9 场 · AstraZeneca 8 场 · Daiichi Sankyo Europe GmbH 4 场 · Medscape Education Global 3 场 · Pfizer 2 场 · Amgen 2 场 · Boehringer Ingelheim 1 场 · Eli Lilly and Company 1 场 · Servier 1 场 · MSD
指南与标准1 个系列
AstraZeneca
心衰诊疗排障：真实世界中优化指南指导的药物治疗
Troubleshooting heart failure: optimising guideline-directed-medical therapy in real-world practice
心力衰竭排查：真实世界中优化指南指导的药物治疗
Troubleshooting heart failure: optimising guideline-directed-medical therapy in real-world practice
血脂管理10 个系列
Daiichi Sankyo Europe GmbH
2026 血脂管理：真正改变结局的决策
Lipid management in 2026: decisions that actually change outcomes
2026 年血脂管理：真正改变结局的决策
Lipid management in 2026: decisions that actually change outcomes
AstraZeneca
Reimagining low-density lipoprotein cholesterol management, driving meaningful action – LD
欢迎来到低密度脂蛋白胆固醇行动实验室
Welcome to the low-density lipoprotein cholesterol action lab
轮转 1——行动站 A：你下一步会怎么做？行动站 B：AI 驱动的心血管风险检测；行动站 C：梳理错失的机会与解决方案
Rotation 1
Action station A: what would you do next?
Action station B: AI-powered cardiovascular risk detection
Action station C: mapping missed opportunities and solutions
轮转 2——行动站 A：你下一步会怎么做？行动站 B：AI 驱动的心血管风险检测；行动站 C：梳理错失的机会与解决方案
Rotation 2
Action station A: what would you do next?
Action station B: AI-powered cardiovascular risk detection
Action station C: mapping missed opportunities and solutions
轮转 3——行动站 A：你下一步会怎么做？行动站 B：AI 驱动的心血管风险检测；行动站 C：梳理错失的机会与解决方案
Rotation 3
Action station A: what would you do next?
Action station B: AI-powered cardiovascular risk detection
Action station C: mapping missed opportunities and solutions
低密度脂蛋白胆固醇行动计划
The low-density lipoprotein cholesterol action plan
Amgen
脂蛋白(a) 与心血管疾病：紧跟进展与新认识
Lipoprotein(a) in cardiovascular disease: keeping up the pace – new insights
欢迎与介绍
Welcome and introduction
Lp(a) 证据的新洞见与迎接靶向 Lp(a) 的未来
New insights in Lp(a) evidence and preparing for Lp(a) targeted future
实施系统性脂蛋白(a)检测是否具有成本效益？
Would it be cost-effective to implement systematic Lp(a)-testing?
脂蛋白(a) 与心血管疾病：紧跟步伐——新洞见讨论
Lipoprotein(a) in cardiovascular disease: keeping up the pace – new insights - discussion
会议评估 / 核心要点
Session evaluation / key learnings
AstraZeneca
从指南到行动：LDL-C 管理的真实世界路径辩论（系列共 3 场）
From guidelines to action - Debating real-world approaches to low-density lipoprotein cholesterol management
开场铺垫
Setting the scene
问题一：何时应强化治疗？
Question 1: when should treatment be intensified?
附：Where do you stand? Audience poll 1
问题二：为什么低密度脂蛋白胆固醇监测很重要？
Question 2: why does low-density lipoprotein cholesterol monitoring matter?
附：Where do you stand? Audience poll 2
专家亮相
Experts under the spotlight
附：Closing reflections and final audience poll
… 另 1 项讲题
Daiichi Sankyo Europe GmbH
斑块漫谈：从数字到降脂治疗的行动
Plaque talk: from numbers to action in lipid-lowering therapy
斑块对话：从数字到降脂治疗的行动
Plaque talk: from numbers to action in lipid-lowering therapy
AstraZeneca
重构 LDL-C 管理，推动有意义的行动——LDL-C 行动实验室（系列共 3 场）
Reimagining low-density lipoprotein cholesterol management, driving meaningful action - LDL-C Action Lab
欢迎来到低密度脂蛋白胆固醇行动实验室
Welcome to the low-density lipoprotein cholesterol action lab
轮转 1——行动站 A：你下一步会怎么做？行动站 B：AI 驱动的心血管风险检测；行动站 C：梳理错失的机会与解决方案
Rotation 1
Action station A: what would you do next?
Action station B: AI-powered cardiovascular risk detection
Action station C: mapping missed opportunities and solutions
轮转 2——行动站 A：你下一步会怎么做？行动站 B：AI 驱动的心血管风险检测；行动站 C：梳理错失的机会与解决方案
Rotation 2
Action station A: what would you do next?
Action station B: AI-powered cardiovascular risk detection
Action station C: mapping missed opportunities and solutions
轮转 3——行动站 A：你下一步会怎么做？行动站 B：AI 驱动的心血管风险检测；行动站 C：梳理错失的机会与解决方案
Rotation 3
Action station A: what would you do next?
Action station B: AI-powered cardiovascular risk detection
Action station C: mapping missed opportunities and solutions
低密度脂蛋白胆固醇行动计划
The low-density lipoprotein cholesterol action plan
轮转 2——行动站 A：你下一步会怎么做？行动站 B：AI 驱动的心血管风险检测；行动站 C：梳理错失的机会与解决方案
Rotation 2
Action Station A: what would you do next?
Action Station B: AI-powered cardiovascular risk detection
Action Station C: mapping missed opportunities and solutions
… 另 1 项讲题
Daiichi Sankyo Europe GmbH
变革 LDL-C 管理：从准确风险评估到联合治疗
Transforming low-density lipoprotein cholesterol care: from correct risk assessment to combination therapies
欢迎与介绍
Welcome and introduction
正确的风险、正确的治疗：SANTORINI 研究的启示
Correct risk, correct treatment: insights from SANTORINI
结局试验证据：降低 LDL-C 与心血管获益
Evidence from outcome trials: low-density lipoprotein cholesterol reduction and cardiovascular benefit
从试验证据到真实世界实践：疗效、安全性特征与风险降低
From trial evidence to real-world practice: efficacy, safety profiles and risk reduction
口服联合治疗：弥合 LDL-C 差距
Oral combination therapy: closing the low-density lipoprotein cholesterol gap
问答
Q&A
… 另 1 项讲题
Daiichi Sankyo Europe GmbH
贝派地酸融入临床实践：不同治疗场景下的 LDL-C 降幅
Integrating bempedoic acid into clinical practice: effectiveness in LDL-C reduction across treatment settings
将贝派地酸融入临床实践：不同治疗场景中降低 LDL-C 的有效性
Integrating bempedoic acid into clinical practice: effectiveness in LDL-C reduction across treatment settings
Medscape Education Global
血脂管理新篇章：拓展治疗边界
A new chapter in lipid control: expanding the therapeutic horizon
设定背景：高危患者的未满足需求
Setting the stage: the unmet need in high-risk patients
从逐步到迅速：早期启动联合治疗的理由
From stepwise to swift: the rationale for early initiation of combination therapy
血脂控制的新篇章：科学
A new chapter for lipid control: the science
血脂控制的新篇章：证据
A new chapter for lipid control: the evidence
展望血脂异常管理的未来——讨论
Envisioning the future of dyslipidaemia management - discussion
闭幕致辞与 EBAC 评估
Closing remarks and EBAC evaluation
Daiichi Sankyo Europe GmbH
2026 血脂管理：真正改变结局的决策——病例讨论
Lipid management in 2026: decisions that actually change outcomes - a case-based discussion
2026 年血脂管理：真正改变结局的决策——基于病例的讨论
Lipid management in 2026: decisions that actually change outcomes - a case-based discussion
综合与其他15 个系列
Eli Lilly and Company
隐匿风险，明确指引：动脉粥样硬化性心血管病的卓越预防策略
Hidden risk, clear guidance: strategies for excellence in atherosclerotic cardiovascular disease (ASCVD) prevention
引言与开场投票
Introduction and opening poll
超越标准危险因素——识别隐匿 ASCVD 风险与 Lp(a) 的作用
Beyond standard risk factors - identifying hidden ASCVD risk and recognising the role of Lp(a)
从危险分层到行动——通过循证且以患者为中心的 ASCVD 管理强化预防
From risk stratification to action — intensifying prevention through evidence-based and patient-centered ASCVD management
互动讨论：在实践中应用 Lp(a) 指导的危险分层与治疗强化
Interactive discussion: applying Lp(a)-informed risk stratification and treatment intensification in practice
总结与闭幕
Summary & closure
Medscape Education Global
家族性乳糜微粒血症综合征的临床表现：提升识别、诊断与管理
The clinical face of familial chylomicronemia syndrome: improving recognition, diagnosis, and management
引言与概述
Introduction and overview
识别临床型家族性乳糜微粒血症综合征："那个被所有人认为只是不依从的患者"
Recognising clinical familial chylomicronemia syndrome: "the patient everyone thought was just noncompliant"
基于临床标准诊断家族性乳糜微粒血症综合征
Diagnosing familial chylomicronemia syndrome based on clinical criteria
家族性乳糜微粒血症综合征治疗的新时代：“现在有何变化？”
A new treatment era for familial chylomicronemia syndrome: “what changes now?”
展望未来靶点
Looking ahead at future targets
要点回顾、听众问答与 EBAC 评估
Key takeaways, audience Q&A, and EBAC evaluation
Daiichi Sankyo Europe GmbH
心脏康复实践：连接证据与患者照护
Cardiac rehabilitation in practice: bridging evidence and patient care
心脏康复实践：连接证据与患者照护
Cardiac rehabilitation in practice: bridging evidence and patient care
Amgen
心血管代谢风险：重建失衡的系统
Cardiometabolic risk: balancing the unstable system
欢迎与学习目标——作为不稳定系统的心血管代谢风险
Welcome and learning objectives - cardiometabolic risk as an unstable system
心血管风险评估与管理中的应做、不应做与大胆尝试
Do’s, don’ts and dares in cardiovascular risk assessment and management
从证据到地平线：试验、治疗前沿与精准预防
From evidence to horizon: trials, therapeutic frontiers and precision prevention
LDL-C 尽早还是更早
LDL-C early or earlier still
超越 LDL-C：其他危险因素的分量
Beyond LDL-C the weight of other risk factors
最后的刺痛
The sting in the tail
… 另 2 项讲题
Daiichi Sankyo Europe GmbH
口服联合治疗的真实世界洞察：贝派地酸的患者特征与疗效
Real-world insights into oral combination therapy: patient characteristics and effectiveness of bempedoic acid
口服联合治疗的真实世界见解：贝派地酸的临床特征与有效性
Real-world insights into oral combination therapy: patient characteristics and effectiveness of bempedoic acid
Medscape Education Global
揭示病毒触发因素：成人免疫接种与心血管风险机制——病例探讨
Unmasking viral triggers: adult immunisation and the mechanisms of cardiovascular risk - a case-based exploration
欢迎与介绍
Welcome and introduction
隐藏的敌人——病毒感染机制与心血管风险
The hidden enemy - mechanisms of viral infection and cardiovascular risk
疫苗作为第四支柱——数据与建议
The vaccine as the fourth pillar - data and recommendations
识别易损患者——基于病例的实施
Identifying the vulnerable patient - case-based implementation
问答、总结与 EBAC 评估
Q&A, conclusion, and EBAC evaluation
Pfizer
不只是呼吸道病毒：RSV、心血管风险与预防的必要性
More than a respiratory virus: respiratory syncytial virus, cardiovascular risk, and the case for prevention
为什么呼吸道合胞病毒在心脏病学中很重要：开场铺垫
Why respiratory syncytial virus matters in cardiology: setting the scene
呼吸道感染未被认识的心血管后果
The unrecognised cardiovascular consequences of respiratory infection
呼吸道合胞病毒疫苗接种的真实世界证据：DAN-RSV 研究
Real-world evidence on respiratory syncytial virus vaccination : the DAN-RSV study
如何帮助患者预防呼吸道合胞病毒疾病：将证据转化为心血管实践
How to help prevent respiratory syncytial virus disease in your patients: translating evidence into cardiovascular practice
核心要点与行动号召
Key take‑home messages and call to action
Boehringer Ingelheim
通往心血管健康之路：白蛋白尿作为关键心血管风险标志物（系列共 2 场）
The road to cardiovascular health: albuminuria as a key cardiovascular risk marker
通往心血管健康之路：白蛋白尿作为关键心血管风险标志物
The road to cardiovascular health: albuminuria as a key cardiovascular risk marker
Servier
一个连续谱，一套策略：心血管代谢疾病的整体管理
One continuum, one strategy: managing cardiometabolic diseases as one
引言
Introduction
早期心血管代谢控制：从源头降低风险
Early cardiometabolic control: reducing risk from the start
治疗依从性差是下一个心血管危险因素吗？
Is poor adherence to treatment the next cardiovascular risk factor?
一个连续体、一个策略：将心血管代谢疾病作为整体管理——讨论与问答
One continuum, one strategy: managing cardiometabolic diseases as one - Discussion and Q&A
一个连续体、一个策略：将心血管代谢疾病作为整体管理——总结
One continuum, one strategy: managing cardiometabolic diseases as one - Conclusion
Pfizer
将呼吸道疾病疫苗接种纳入心血管照护
Integrating vaccination for prevention of respiratory disease into cardiovascular care
将预防呼吸道疾病的疫苗接种整合进心血管诊疗
Integrating vaccination for prevention of respiratory disease into cardiovascular care
MSD
从风险到责任：多方对话回应心血管流行，纳入患者声音
From risk to responsibility: responding to the cardiovascular epidemic through a multi-stakeholder dialogue integrating patient voices
设定挑战
Setting the challenge
临床视角：低密度脂蛋白讨论中还缺什么？
Clinical perspective: what’s missing in low-density lipoprotein discussions
患者倡导者视角
Patient advocate perspective
专家讨论：落实实践变革
Panel discussion: implementing practice change
明确的行动号召
Clear call to action
Pfizer
DAN-RSV 研究聚焦：证据、解读与临床意义
The DAN-RSV trial in focus: evidence, interpretation, and clinical relevance
聚焦 DAN-RSV 试验：证据、解读与临床相关性
The DAN-RSV trial in focus: evidence, interpretation, and clinical relevance
Medscape Education Global
数据说话：流感疫苗接种心脏保护作用的临床证据
The data speaks: clinical evidence for cardioprotection through influenza vaccination
欢迎与介绍：免疫接种作为心血管保护
Welcome and introduction: immunisation as cardiovascular protection
炎症浪潮：流感如何损害心脏
The inflammatory surge: how influenza damages the heart
病例 1——心衰守护者：预防失代偿
Case 1 – The heart failure defender: preventing decompensation
病例 2——克服万难：免疫功能低下老年人的保护
Case 2 – Against all odds: protection for the immunocompromised older adult
问答、总结致辞与 EBAC 评估
Q&A, concluding remarks, and EBAC evaluation
AstraZeneca
高钾血症管理入门：助力 RAAS 抑制剂优化使用
Hyperkalaemia management 101: supporting renin-angiotensin-aldosterone system inhibitor optimisation
高钾血症管理入门：支持肾素-血管紧张素-醛固酮系统抑制剂优化
Hyperkalaemia management 101: supporting renin-angiotensin-aldosterone system inhibitor optimisation
Daiichi Sankyo Europe GmbH
心血管预防门诊实践：真实世界经验、患者获益与多学科协作——专家最佳实践交流
Cardiovascular prevention clinics in practice: real-world experience, patient benefits, and multidisciplinary collaboration - a best practice exchange between experts
心血管预防门诊实践：真实世界经验、患者获益与多学科协作——专家最佳实践交流
Cardiovascular prevention clinics in practice: real-world experience, patient benefits, and multidisciplinary collaboration - a best practice exchange between experts
企业卫星会内容由赞助方支持，此处仅作学术日程信息陈列，不代表编辑立场。